Frost P, Kerbel R S
Cancer Metastasis Rev. 1983;2(3):239-56. doi: 10.1007/BF00048480.
The application of immunologic methods to the treatment of neoplasia has been a goal of research in tumor immunology. Unfortunately, no clearly defined success for such therapy has been achieved. However, the most recent advances in tumor biology have provided for a more valid conceptual framework upon which to plan further research in this area. The more general awareness of tumor progression and heterogeneity, particularly in the context of tumor metastasis, while imposing a sense of gloom regarding all therapeutic modalities, shifted immunologic thinking toward the development of nonspecific modalities. We herein propose that this 'shift' may be premature and that immunotherapy using cytolygic T cells could still be feasible. Our views are based on newer approaches for selecting immunogenic variants of malignant tumors and a better understanding of the relationship of the immune response to metastases.
将免疫方法应用于肿瘤治疗一直是肿瘤免疫学研究的目标。不幸的是,这种疗法尚未取得明确的成功。然而,肿瘤生物学的最新进展为在该领域规划进一步研究提供了更有效的概念框架。对肿瘤进展和异质性的更普遍认识,特别是在肿瘤转移的背景下,虽然给所有治疗方式带来了一种悲观情绪,但却将免疫治疗的思路转向了非特异性治疗方式的开发。我们在此提出,这种“转变”可能为时过早,使用细胞毒性T细胞的免疫疗法仍然可行。我们的观点基于选择恶性肿瘤免疫原性变体的新方法以及对免疫反应与转移关系的更好理解。